3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
679
Carcinoma, Non-Small-Cell Lung
324
Neoplasms
168
Breast Neoplasms
163
Urinary Bladder Neoplasms
157
Lung Neoplasms
157
Neoplasm Metastasis
139
Cholangiocarcinoma
112
Ovarian Neoplasms
106
Biliary Tract Neoplasms
92
Lymphoma, Large B-Cell, Diffuse
73
Nasopharyngeal Carcinoma
70
Lymphoma
66
Sarcoma
63
Recurrence
62
Gallbladder Neoplasms
60
Carcinoma, Transitional Cell
55
Triple Negative Breast Neoplasms
54
Hodgkin Disease
52
Colorectal Neoplasms
49
Fallopian Tube Neoplasms
48
Lymphoma, Non-Hodgkin
47
Adenocarcinoma
45
Bile Duct Neoplasms
40
Carcinoma, Ovarian Epithelial
31
Non-Muscle Invasive Bladder Neoplasms
30
Uterine Cervical Neoplasms
28
Carcinoma
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma of Lung
27
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Oncolytic Virotherapy
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Bevacizumab
2
valrubicin
1
thymoglobulin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Tenofovir
1
Rituximab
1
Radiotherapy, Intensity-Modulated
1
Papillomavirus Vaccines
1
Nimorazole
1
Mitomycin
1
Lamivudine
1
Kidney Transplantation
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Gemcitabine
1
Gels
1
Fluorescent Antibody Technique
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Virus Diseases
×
Gemcitabine
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled